Please assess the completion status of the following clinical trial:

Trial Title: ED Recovery in Men Age </=65 Treated With Bilateral Nerve Sparing Robotic Assisted Prostatectomy for Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria~* All patients undergoing BNS-RAP for prostate cancer will be asked to participate~* Ability to achieve erections sufficient for intercourse prior to surgery and an SHIMS-5 score of \>= 22~* Must maintain follow up care at COH for visits 1, 3, 6, 9, 12, and 18 months post surgery~* Participants willing to participate on study for a minimum of 18 months~* Consented participant on the Prostate database study (protocol 00149)~* Patients must have a clinical stage of \< T3~* Gleason score \< 8 on post-operative pathological sample prior to randomization~Exclusion Criteria~* Metastatic disease~* Coronary artery disease on nitrate therapy (including oral sublingual nitrates)~* Unable to maintain follow up visits at COH at 1, 3, 6, 9, 12, and 18 months post-operatively~* Pathology diagnosis \>= pT3~* Prior hormonal treatment use for prostate cancer or low serum testosterone~* Allergy to prostaglandin PGE1, Lidocaine, or Viagra~* Gleason score \>= 8 on post-operative pathological sample prior to randomization~* Concomitant use of cytochrome P450 3AY inhibitors (cimetidine, erythromycin, ketoconazole, or protease inhibitors)~* SHIMS-5 score =\< 21

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Sildenafil Citrate/Mo+Aprostadil/day (Type: EXPERIMENTAL): Patients receive intraurethral alprostadil once daily for up to 9 months in the absence of disease progression or unacceptable toxicity. Patients also receive 3 doses of oral sildenafil citrate at least 48 hours apart monthly for up to 18 months. Patients on all three arms will have undergone robotic-assisted laparoscopic surgery. All patients will take part in the questionnaire administration and quality-of-life assessments.
- Sildenafil Citrate Monthly (Type: ACTIVE_COMPARATOR): Patients receive 3 doses of oral sildenafil citrate on 3 separate occasions at least 48 hours apart monthly for 18 months. Patients on all three arms will have undergone robotic-assisted laparoscopic surgery. All patients will take part in the questionnaire administration and quality-of-life assessments.
- Daily Sildenafil Citrate (Type: EXPERIMENTAL): Patients receive oral sildenafil citrate once daily for up to 9 months in the absence of disease progression or unacceptable toxicity. Patients also receive 3 doses of oral sildenafil citrate at least 48 hours apart monthly for up to 18 months. Patients on all three arms will have undergone robotic-assisted laparoscopic surgery. All patients will take part in the questionnaire administration and quality-of-life assessments.

Based on this trial design, predict the completion outcome and termination type (if applicable).